1. Introduction {#s1}
===============

Heart failure is characterized by structural abnormalities of left ventricular dysfunction and dilatation, a compensatory rise in systemic vascular resistance secondary to activation of neurohumoral pathways,[@b1] inflammation,[@b2] and metabolic adaptations to energy substrate utilization.[@b3] It is a major public health problem globally, causing significant mortality and morbidity and placing a significant burden on healthcare systems. Hospitalization rate, a measure of healthcare resource utilization, is estimated to be 20% at one month and 50% at 6 months.[@b4] A history of hospitalization is itself an independent predictor of long-term mortality. Therefore, measures to reduce hospitalization are likely beneficial in this patient population.[@b5]

Telemonitoring can be used to track patients\' symptoms, adherence to medications and objective parameters such as blood pressure, heart rate, body weight and urine output.[@b6] However, the effectiveness of body weight monitoring has been disputed, as the largest randomized controlled trials to date failed to demonstrate a reduction in heart failure-related hospitalizations. The reasons behind this are complex, but can be partly explained by the fact that body weight and symptoms may not provide sufficient warning of impending decompensation of cardiac function.[@b7],[@b8] Patient data from implantable hemodynamic monitoring studies have shown that weight is not a good measure of filling pressures that may be important determinants of decompensation.[@b9] Moreover, hospitalization in heart failure may be related to not only abnormal physiological factors, but also social factors.[@b10]

In addition to tele-monitoring, recent interests have focused on the roles of implantable hemodynamic monitors. Three devices, CardioMEMS, Chronicle and HeartPOD are commercially available to monitor pulmonary arterial pressure, right ventricular pressure and left atrial pressure, respectively. Several meta-analyses have been performed on remote monitoring for heart failure. For example, in 2009, the impact of remote monitoring on mortality and hospitalization rates was examined.[@b11] Recently, two meta-analyses of randomized controlled trials were performed.[@b12],[@b13] This study complements these previous studies by providing an updated meta-analysis of both randomized controlled trials and observational studies on hospitalization rates.

2. Methods {#s2}
==========

2.1. Search strategy, inclusion and exclusion criteria {#s2a}
------------------------------------------------------

This systematic review and meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.[@b14] It has been registered with PROSPERO (CRD42017073934). PubMed and Cochrane Library were searched up to 1^st^ May 2017, with no language restriction, for studies that investigated the hospitalization rates in heart failure. The following search terms were used for PubMed and Cochrane Library: "telemonitoring heart failure hospitalization" and "hemodynamic monitoring heart failure hospitalization).

The following inclusion criteria were applied: (1) the design was a case-control, prospective or retrospective observational study or randomized controlled trial in humans, (2) patients with heart failure (both preserved and reduced ejection fraction included) were analyzed, (3) hospitalization rates, whether heart failure-specific, cardiovascular-related or all-cause, were reported or could be calculated from the published data; (3) and (4) hazard ratios (HRs) or relative risks (RRs) and their corresponding 95% CIs or data necessary to calculate these were available.

Quality assessment of case-control and cohort studies included in our meta-analysis was performed using the Newcastle--Ottawa Quality Assessment Scale (NOS) ([Tables 1S](#st01){ref-type="supplementary-material"} and [2S](#st02){ref-type="supplementary-material"} for telemonitoring, [Tables 3S](#st03){ref-type="supplementary-material"} and [4S](#st04){ref-type="supplementary-material"} for hemodynamic monitoring),[@b15] and of randomized controlled trials using the Jadad scale (Oxford quality scoring system) ([Table 5S](#st05){ref-type="supplementary-material"} and [6S](#st06){ref-type="supplementary-material"} for telemonitoring and hemodynamic monitoring, respectively). The NOS evaluated the categories of study participant selection, comparability of the results, and quality of the outcomes. The following characteristics were assessed: (1) representativeness of the exposed cohort; (2) selection of the non-exposed cohort; (3) ascertainment of exposure; (4) demonstration that outcome of interest was not present at the start of study; (5) comparability of cohorts on the basis of the design or analysis; (6) assessment of outcomes; (7) follow-up period sufficiently long for outcomes to occur; and (8) adequacy of follow-up of cohorts. This scale varied from zero to nine stars, which indicated that studies were graded as poor quality if they met \< 5 criteria, fair if they met 5 to 7 criteria, and good if they met \> 8 criteria. The Jadad score assessed the quality by the following criteria of (1) randomization, (2) allocation concealment, (3) double blinding and (4) withdrawal and dropouts. The total score is 7, scores 1 to 3 indicate low quality and 4 to 7 high quality.

2.2. Data extraction and statistics {#s2b}
-----------------------------------

Data from the different studies were entered in pre-specified spreadsheet in Microsoft Excel. All potentially relevant reports were retrieved as complete manuscripts and assessed for compliance with the inclusion criteria. In this meta-analysis, the extracted data elements consisted of: (1) publication details: last name of first author, publication year and locations; (2) study design (cohort study or randomized controlled trial); (3) follow-up duration; (4) endpoints; (5) the quality score; and (6) the characteristics of the population including sample size, gender, age and number of subjects. Meta-analyses of observational studies are challenging due to differences in study designs and inherent biases. Two reviewers independently reviewed each included study and disagreements were resolved by adjudication with input from a third reviewer.

The endpoints for this meta-analysis were hospitalization rates. Where different types of hospitalization rates were reported, heart failure-specific rates were used preferentially, followed by cardiovascular-related hospitalization rates, and finally all-cause hospitalization rates. Multivariate adjusted hazard ratios (HRs) or relative risks (RRs) with 95% CI were extracted for each study. When values from multivariate analysis were not available, those from univariate analysis were used.

When HRs were not provided, they were calculated using raw data. The pooled adjusted risk estimates from each study as the HR values with 95% CI were presented. Different types of hospitalization rates were pooled together.

Heterogeneity between studies was determined using Cochran\'s Q, which is the weighted sum of squared differences between individual study effects and the pooled effect across studies, and the *I*^2^ statistic from the standard chi-square test, which is the percentage of the variability in effect estimates resulting from heterogeneity. *I*^2^ \> 50% was considered to reflect significant statistical heterogeneity. A fixed effects model was used if *I*^2^ \< 50%, otherwise the random-effects model using the inverse variance heterogeneity method was selected. To find the origin of the heterogeneity, sensitivity analysis excluding one study at a time was performed. Subgroup analyses based on time-points or type of telemonitoring or hemodynamic monitoring were performed. Short-term was defined as those occurring within 6 months, whereas long-term was defined as 12 months or longer. Where a study reported effective estimates at successive time points, the longer time point was used. Funnel plots, Begg and Mazumdar rank correlation test and Egger\'s test[@b16] were used to assess for possible publication bias.

3. Results {#s3}
==========

[Figure 1](#jgc-15-04-298-g001){ref-type="fig"} shows a flow diagram detailing the search strategy and study selection process. For telemonitoring, a total of 120 and 111 entries were retrieved from PubMed and Cochrane Library, with 60 articles included in our final meta-analysis.[@b6],[@b17]--[@b75] For hemodynamic monitoring, a total of 220 and 53 entries were retrieved from the same databases, with 12 articles included in our final meta-analysis.[@b4],[@b76]--[@b86]

3.1. Telemonitoring {#s3a}
-------------------

For telemonitoring, a total of 31,501 patients (mean age: 68 ± 12 years old; 61% male) were included. The baseline characteristics of these studies are listed in [Table 1](#jgc-15-04-298-t01){ref-type="table"}. Six were cohort studies and 55 were randomized controlled trials. The mean follow-up duration was 11 ± 8 months. Telemonitoring reduced hospitalization rates with a HR of 0.73 (95% CI: 0.65--0.83; *P* \< 0.0001, [Figure 2](#jgc-15-04-298-g002){ref-type="fig"}). The Cochran\'s Q value was greater than the degrees of freedom (994 *vs*. 59), suggesting the true effect size was different among the various studies. Moreover, *I*^2^ took a value of 94%, indicating the presence of significant heterogeneity. Sensitivity analysis by leaving out one study at a time did not significantly alter the pooled HR ([Figure 1S](#s01){ref-type="fig"}). Funnel plot plotting standard errors or precision against the logarithms of the odds ratio are shown in [Figures 2S](#s02){ref-type="fig"} and [3S](#s03){ref-type="fig"}, respectively. Begg and Mazumdar rank correlation suggested a significant publication bias (Kendal\'s Tau value = --0.2, *P* \< 0.05); Egger\'s test demonstrated significant asymmetry (intercept: --1.4, *t*-value: 2.6; *P* \< 0.05).

![A flow diagram detailing the search strategy and study selection process for this systematic review and meta-analysis on the effects of telemonitoring and hemodynamic monitoring on hospitalization rates in heart failure.](jgc-15-04-298-g001){#jgc-15-04-298-g001}

###### Characteristics of the 60 studies on telemonitoring included in this meta-analysis.

  First author / Year          Study design   Sample size (*n*)   Age   SD   \% Male   Ejection fraction, %           Endpoints           Follow-up (months)                                                                                                      Variables in multivariate model
  --------------------------- -------------- ------------------- ----- ---- --------- ---------------------- --------------------------- -------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gallagher 2017                   RCT               40           64    20     75               25                  All-cause, HF                 1                                                                                                                        (Univariate)
  Sardu 2016                       RCT               183          72    7      76             \< 35                      HF                       12                                                                                           Age, chronic kidney disease, hypercholesterolaemia, LVEF, NYHA class
  Hale 2016                        RCT               25           72    11     64               \-                  All-cause, HF                 3                                                                                                                        (Univariate)
  Ong 2016                         RCT              1437          73    \-     54               43                    All-cause                  3, 6          Age, sex, race/ethnicity, insurance, comorbidities based on the Health Care Utilization Project methods, 6 year and quarter of enrollment, social isolation as measured by the Lubben Social Network Scale score, 31 and income level
  Kraai 2016                       RCT               177          69    16     37               27                       HF                       9                                                                                                                        (Univariate)
  Smolis-Bąk 2015                 Cohort             52           62    9      90               25                    All-cause                   18                                                                                                                       (Univariate)
  Kao 2016                        Cohort            1246          78    12     54               \-                    All-cause                   36                                                                                                                       (Univariate)
  Idris 2015                       RCT               28           63    \-     39               23                     Cardiac                   3, 6                                                                                                                      (Univariate)
  Pedone 2015                      RCT               90           80    7      39               46                  All-cause, HF                 6                                                                                                                        (Univariate)
  Bekelman 2015                    RCT               384          68    14     97               \-                    All-cause                   12                                                                                                                       (Univariate)
  Vuorinen 2014                    RCT               94           58    17     83               28                       HF                       6                                                                                                                        (Univariate)
  Blum 2014                        RCT               203          73    13     71               29                    All-cause                   48                                                                                               Age, gender, practice region (RRMA), and baseline NYHA class
  Giacomelli 2014                  RCT               285          80    \-     60               \-                    All-cause                   9                                                                                                                        (Univariate)
  Martín-Lesende 2013              RCT               58           81    8      59               \-            All-cause, cause-specific         6, 12                                                                                                                      (Univariate)
  Krum 2013                        RCT               405          73    15     63               36                  All-cause, HF                 12                                                                                               Age, gender, practice region (RRMA), and baseline NYHA class
  Sabatier 2013                    RCT               90           \-    \-     \-               \-                       HF                       3                                                                                                                        (Univariate)
  Boyne 2012                       RCT               382          71    11     59               36                  All-cause, HF                 12                                                                               Ischaemia, blood urea, haemoglobin level, heart rate, NYHA class, and systolic blood pressure
  Lyngå 2012                       RCT               319          73    10     75               \-               All-cause, cardiac               12                                                                                                                       (Univariate)
  Seto 2012                        RCT               84           54    19     59               38                    All-cause                   6                                                                                                                        (Univariate)
  Dendale 2012                     RCT               160          76    10     65               35                  All-cause, HF                 6                                                                                                                        (Univariate)
  Koehler 2012                     RCT               670          67    15     86              267             All-cause, cardiac, HF             26                                                                                                                       (Univariate)
  Kurtz 2011                      Cohort             138          68    17     78               32                       HF                       12                                                            Age, state of residence, presence of various comorbid conditions, and prior cardiac events including coronary artery bypass surgery
  Wade 2011                        RCT               316          77    10     53               \-               All-cause, cardiac               6                                                                                                                        (Univariate)
  Domingo 2011                     RCT               92           66    12     71               36            Cardiac excluding HF, HF            12                                                                                                                       (Univariate)
  Howlett 2011                     RCT               122          67    \-     65               46                    All-cause                   12                                                                                                                       (Univariate)
  Juan 2011                       Cohort             120          76    \-     \-               \-                    All-cause                   30                                                                                                                       (Univariate)
  Chaudhry 2010                    RCT              1653          61    16     58               \-                  All-cause, HF                 9                                                                                                                        (Univariate)
  Antonicelli 2010                 RCT               57           78    7      58               \-                       HF                       12                                                                                                                       (Univariate)
  Delaney 2010                     RCT               24           79    12     42               \-                  All-cause, HF                 3                                                                                                                        (Univariate)
  Peters-Klimm 2010                RCT               199          70    14     72               \-                  All-cause, HF                 12                                                                                                                       (Univariate)
  Bowles 2009                      RCT               303          75           37               \-                       HF                       2                                                                                                                        (Univariate)
  Scherr 2009                      RCT               108          66    11     79               25                    All-cause                   6                                                                                                                        (Univariate)
  Mortara 2009                     RCT               461          60    17     86               29                  All-cause, HF                 12                                                                                      New York Heart Association class, β-blocker use at baseline, sex, and Na levels
  Dar 2009                         RCT               182          71    16     66               \-                  All-cause, HF                 6                                                                                                                        (Univariate)
  Goode 2009                       RCT               201          70    11     70               24                    All-cause                   16                                                                                                                       (Univariate)
  Brown 2008                       RCT              14663         \-    \-     \-               \-                    All-cause                   12                                                                                                                       (Univariate)
  Soran 2008                       RCT               315          76    10     31               24                  All-cause, HF                 6                                                                                       New York Heart Association class, β-blocker use at baseline, sex, and Na levels
  Antonicelli 2008                 RCT               57           78    10     58               36                       HF                       12                                                                                                                       (Univariate)
  Morguet 2008                 Case-control          128          60    14     88               44               All-cause, cardiac               10                                                                                                                       (Univariate)
  Kashem 2008                      RCT               48           54    15     73               26                  All-cause, HF                 12                                                                                                                       (Univariate)
  Woodend 2008                     RCT               121          67    17     72               \-                  All-cause, HF               3, 12                                                                                                                      (Univariate)
  Sisk 2006                        RCT               406          59    19     54                                     All-cause                   12                                                                                                                       (Univariate)
  Riegel 2006                      RCT               134          72    11     46               43                    All-cause                   6                                                                                                                        (Univariate)
  Hudson 2005                     Cohort             91           74    11     53               \-                    All-cause                   6                                                                                                                        (Univariate)
  GESICA Investigators 2005        RCT              1518          65    13     71               \-             All-cause, cardiac, HF             16                                                                                        NYHA class, age, baseline treatment, comorbidity, and systolic dysfunction
  Dunagan 2005                     RCT               151          \-    \-     47                                   All-cause, HF                 12                                                                                  Severely impaired LV function, NYHA class, use of target or high doses of ACE inhibitor
  Cleland et al. (2005)            RCT               253          67    16     53               25             All-cause, cardiac, HF             8                      Age, NT proBNP, body mass index, systolic and diastolic blood pressure, hemoglobin, sodium, urea, creatinine, NYHA functional classification, loop and potassium-sparing diuretics, ACE inhibitors, beta blockers
  Schofield 2005                  Cohort             73           67    11     99               23                    All-cause                   6                                                                                                                        (Univariate)
  Capomolla 2004                   RCT               133          57    10     47               29             All-cause, cardiac, HF             12                                                                                                                       (Univariate)
  Galbreath 2004                   RCT              1069          71    10     71               54                  All-cause, HF               6, 18                                                                                                                      (Univariate)
  DeBusk 2004                      RCT               462          72    11     51               \-             All-cause, cardiac, HF             12                                                                                                                       (Univariate)
  Roth 2004                       Cohort             118          74    9      69               24                    All-cause                   12                                                                                                                       (Univariate)
  Goldberg 2003                    RCT               208          59    15     68             \< 35              All-cause, cardiac               6                                                                                                                        (Univariate)
  Laramee 2003                     RCT               287          71    12     54               \-                  All-cause, HF                1.5                                                                                                                       (Univariate)
  McDonald 2002                    RCT               98           71    10     66               37                       HF                       3                                                                                                                        (Univariate)
  Riegel 2002                      RCT               358          72    12     49               43                  All-cause, HF                3, 6                                                                                                                      (Univariate)
  Kasper 2002                      RCT               200          62    20     33               27                       HF                       6                                                                                                                        (Univariate)
  Krumholz 2002                    RCT               88           76    13     57               38             All-cause, cardiac, HF             12                                                                                                                       (Univariate)
  Jerant 2001                      RCT               25           70    16     48               \-                  All-cause, HF                 2                                                                                                                        (Univariate)
  Blue 2001                        RCT               165          75    12     58               \-                  All-cause, HF                 12                                                                                                                       (Univariate)

ACE: angiotensin converting enzyme; HF: heart failure; LV: left ventricular; NT proBNP: N-terminal pro brain natriuretic peptide; RCT: randomized controlled trial.

![Pooled hazard ratios for studies examining the effects of telemonitoring on hospitalization rates in heart failure.](jgc-15-04-298-g002){#jgc-15-04-298-g002}

![Pooled hazard ratios for studies examining the effects of hemodynamic monitoring on hospitalization rates in heart failure.](jgc-15-04-298-g003){#jgc-15-04-298-g003}

Because of the substantial heterogeneity present, we explored its possible origins. As we initially combined mortality assessed at different durations, univariate and multivariate HRs, and study design, the following subgroup analyses were performed. Firstly, we found that telemonitoring reduced hospitalization rates in the short-term (*n* = 27; ≤ 6 months; HR = 0.77, 95% CI: 0.65--0.89; *P* \< 0.01; *I*^2^ = 67%; [Figure 4S](#s04){ref-type="fig"}) and long-term (*n* = 32; ≥ 12 months: HR = 0.73, 95% CI: 0.62--0.87; *P* \< 0.0001; *I*^2^ = 97%; [Figure 5S](#s05){ref-type="fig"}). Secondly, subgroup analysis was performed for the type of HR. Meta-analysis of univariate HRs produced a pooled effect estimate of 0.94 (95% CI: 0.93--0.95; *P* \< 0.0001) without significantly affecting heterogeneity (*I*^2^ = 95%, *vs*. 94% previously). By contrast, meta-analysis of multivariate HRs produced a similar pooled effect estimate of 0.91 (95% CI: 0.84--0.99; *P* \< 0.05) whilst reducing *I*^2^ to 71%. Thirdly, subgroup analysis was performed for study design. Meta-analysis of randomized controlled trials (RCTs) yielded a pooled effect estimate of 0.96 (95% CI: 0.95--0.97; *P* \< 0.0001) whilst reducing *I*^2^ to 72%. By contrast, meta-analysis of cohort studies yielded a significantly lower HR of 0.38 (95% CI: 0.36--0.41; *P* \< 0.0001) whilst preserving *I*^2^ at 94%. Together, these findings suggest the duration over which mortality was assessed, type of HRs and study design to be possible sources of heterogeneity.

3.2. Hemodynamic monitoring {#s3b}
---------------------------

For wireless hemodynamic monitoring, a total of 4831 patients were included. The baseline characteristics of these studies are listed in [Table 2](#jgc-15-04-298-t02){ref-type="table"}. Four publications were cohort studies and eight publications were based on data from three randomized controlled trials (CHAMPION, COMPASS-HF and REDUCEhf). The mean follow-up duration was 13 ± 4 months. The mean age was 66 ± 18 years) of whom 66% were male. Wireless hemodynamic monitoring significantly reduced hospitalization rates with a HR of 0.60 (95% CI: 0.53--0.69; *P* \< 0.001). The Cochran\'s Q value was greater than the degrees of freedom (36 *vs*. 13), suggesting the true effect size was different among the various studies. *I*^2^ took a value of 64%, indicating the presence of significant heterogeneity. Sensitivity analysis by leaving out one study at a time did not significantly alter the pooled HR ([Figure 6S](#s06){ref-type="fig"}). Funnel plot plotting standard errors or precision against the logarithms of the odds ratio are shown in [Figures 7S](#s07){ref-type="fig"} and [8S](#s08){ref-type="fig"}, respectively. Begg and Mazumdar rank correlation suggested a significant publication bias (Kendal\'s Tau value = --0.5, *P* \< 0.05). Egger\'s test demonstrated significant asymmetry (intercept: --2.2, *t*-value = 3.2; *P* \< 0.01).

###### Characteristics of the 12 studies on hemodynamic monitoring included in this meta-analysis.

  First author/Year    Study design               Population                Type of hemodynamic monitoring   Sample size (n)   Age, yrs   SD   \% Male   Ejection fraction, %                        Endpoints                        Follow-up (months)   Variables in multivariate model
  ------------------- -------------- ------------------------------------- -------------------------------- ----------------- ---------- ---- --------- ---------------------- ----------------------------------------------------- -------------------- ---------------------------------
  Desai 2017              Cohort                      HF                     Pulmonary arterial pressure          1114            71      11     64               \-                               All-cause, HF                              6                     (Univariate)
  Jermyn 2016             Cohort                      HF                     Pulmonary arterial pressure           77             \-      \-     \-               \-                                    HF                                    12                    (Univariate)
  Adamson 2016             RCT                        HF                     Pulmonary arterial pressure           245            73      8      \-               \-                                    HF                                    17                    (Univariate)
  Abraham 2016             RCT                        HF                     Pulmonary arterial pressure           347            62      18     \-               \-                               All-cause, HF                              17                    (Univariate)
  Raina 2015               RCT                        HF                     Pulmonary arterial pressure           537            62      18     \-               \-                                    HF                                    18                    (Univariate)
  Adamson 2014             RCT        HF with preserved ejection fraction    Pulmonary arterial pressure           119            66      12     60               51                                    HF                                    18                    (Univariate)
                                       HF with reduced ejection fraction                                           66             60      13     76               23                                                                          18                    (Univariate)
  Benza 2015               RCT          HF with pulmonary hypertension       Pulmonary arterial pressure           314            62      13     72               \-                                    HF                                    15                    (Univariate)
                                       HF without pulmonary hypertension                                           236            61      13     74               \-                                    HF                                    15                    (Univariate)
  Adamson 2011             RCT                        HF                      Right ventricular pressure           400            55      21     34               23                               All-cause, HF                              12                    (Univariate)
  Abraham 2011             RCT                        HF                     Pulmonary arterial pressure           550            62      18     73               60                                    HF                                    6                     (Univariate)
  Ritzema 2010            Cohort                      HF                         Left atrial pressure              40             66      10     78               32            Combined HF hospitalization and all-cause mortality           3                     (Univariate)
  Bourge 2008              RCT                        HF                      Right ventricular pressure           274            58      19     65               33                                    HF                                    6                     (Univariate)
  Adamson 2003            Cohort                      HF                      Right ventricular pressure           32             59      10     38               29                                    HF                                    17                    (Univariate)

HF: heart failure; RCT: randomized controlled trial.

Significant reductions in hospitalization rates were observed in both short-term (HR: 0.55, 95% CI: 0.45--0.68; *P* \< 0.001; *I*^2^ = 72%; [Figure 9S](#s09){ref-type="fig"}) and long-term (HR: 0.64, 95% CI: 0.57--0.72; *P* \< 0.001; *I*^2^ = 55%; [Figure 10S](#s10){ref-type="fig"}). For the different types of hemodynamic devices, hospitalization rates were significantly reduced using pulmonary pressure monitoring (HR: 0.58, 95% CI: 0.50--0.66; *P* \< 0.001; *I*^2^ = 67%; [Figure 11S](#s11){ref-type="fig"}) or left atrial pressure monitoring (HR: 0.16, 95% CI: 0.04--0.68; *P* \< 0.05). It was not possible to perform a meta-analysis for left atrial pressure monitoring because this was only assessed by one study. Right ventricular pressure monitoring tended to reduce hospitalization rates (HR: 0.69, 95% CI: 0.47--1.01; *I*^2^ = 61%; Supplementary [Figure 12S](#s12){ref-type="fig"}) but this did not reach statistical significance (*P* = 0.058).

###### Quality ratings for included case-control studies using the Newcastle-Ottawa quality assessment scale for telemonitoring.

  Number    First Author   Selection (score)   Comparability (score)       Total Score                    
  -------- -------------- ------------------- ----------------------- --- ------------- --- ---- ---- --- ---
  1         Morguet 2008          \-                     1             1        1        2   \-   \-   1   6

###### Quality ratings for included cohort studies using the Newcastle-Ottawa quality assessment scale for telemonitoring.

  Number     First Author     Selection (score)   Comparability (score)   Exposure (score)   Total Score                                        
  -------- ----------------- ------------------- ----------------------- ------------------ ------------- ------------------------ ---- --- --- ---
  1            Kao 2016               1                     1                    1                0                  0              1    1   1   6
  2         Smolis-Bąk 2015           1                     1                    1                1        2 (age, comorbidities)   1    1   1   9
  3           Kurtz 2011              1                     1                    1                1            2 (age, LVEF)        1    1   1   9
  4           Hudson 2005             1                     0                    1                1                  0              1    1   1   6
  5         Schofield 2005            1                     1                    1                1                  2              1    1   1   9
  6            Roth 2004              1                     1                    1                1                  2              \-   1   1   8

LVEF: left ventricular ejection fraction.

###### Quality ratings for included case-control studies using the Newcastle-Ottawa quality assessment scale for hemodynamic monitoring.

  Number    First Author   Selection (score)   Comparability (score)        Total Score                  
  -------- -------------- ------------------- ----------------------- ---- ------------- --- --- --- --- ---
  1         Jermyn 2016            1                     1             \-        1        2   1   1   1   8
  2         Abraham 2016           1                     1             1         1        2   1   1   1   9
  3          Raina 2015            1                     1             \-        1        2   1   1   1   8
  4          Benza 2015            1                     1             \-        1        2   1   1   1   8
  5         Abraham 2011           1                     1             1         1        2   1   1   1   9

###### Quality ratings for included cohort studies using the Newcastle-Ottawa quality assessment scale for hemodynamic monitoring.

  Number    First Author   Selection (score)   Comparability (score)   Exposure (score)   Total Score                  
  -------- -------------- ------------------- ----------------------- ------------------ ------------- --- --- --- --- ---
  1          Desai 2017            1                     1                    1                1        2   1   1   1   9
  2         Ritzema 2010          \-                     1                    1                1        2   1   1   1   8
  3         Adamson 2003           1                     1                    1                1        2   1   1   1   9

###### Quality ratings for included randomized controlled trials using the Jadad quality assessment scale for telemonitoring.

  Number              Study             Randomization   Allocation concealment   Double blinding   Withdrawals and dropouts   Total score
  -------- --------------------------- --------------- ------------------------ ----------------- -------------------------- -------------
  1              Gallagher 2017               2                   1                     1                     1                    5
  2                Sardu 2016                 2                   2                     2                     0                    6
  3                 Hale 2016                 1                   0                     0                     1                    2
  4                 Ong 2016                  2                   2                     2                     1                    7
  5                Kraai 2016                 2                   1                     1                     1                    5
  6                Idris 2015                 1                   0                     0                     1                    2
  7                Pedone 2015                1                   1                     2                     1                    5
  8               Bekelman 2015               2                   0                     0                     1                    3
  9               Vuorinen 2014               1                   0                     0                     1                    2
  10                Blum 2014                 1                   0                     0                     1                    2
  11             Giacomelli 2014              1                   0                     0                     1                    2
  12           Martín-Lesende 2013            2                   0                     1                     1                    4
  13                Krum 2013                 1                   1                     1                     1                    4
  14              Sabatier 2013               1                   0                     0                     1                    2
  15               Boyne 2012                 2                   0                     2                     1                    5
  16               Lynga° 2012                1                   1                     2                     1                    5
  17                Seto 2012                 2                   2                     2                     1                    7
  18              Dendale 2012                1                   2                     2                     1                    4
  19              Koehler 2012                2                   1                     1                     1                    5
  20                Wade 2011                 1                   0                     0                     1                    2
  21              Domingo 2011                1                   0                     0                     1                    2
  22              Howlett 2011                1                   0                     0                     1                    2
  23              Chaudhry 2010               2                   2                     2                     1                    7
  24            Antonicelli 2010              1                   0                     0                     1                    2
  25              Delaney 2010                1                   0                     0                     1                    2
  26            Peters-Klimm 2010             2                   2                     2                     1                    7
  27               Bowles 2009                1                   2                     2                     1                    6
  28               Scherr 2009                1                   0                     2                     1                    4
  29              Mortara 2009                2                   2                     2                     1                    7
  30                Dar 2009                  2                   1                     2                     1                    6
  31               Goode 2009                 1                   0                     0                     1                    2
  32               Brown 2008                 2                   1                     0                     1                    4
  33               Soran 2008                 1                   1                     2                     1                    5
  34            Antonicelli 2008              1                   0                     0                     1                    2
  35               Kashem 2008                2                   0                     0                     1                    3
  36              Woodend 2008                1                   0                     0                     1                    2
  37                Sisk 2006                 2                   2                     2                     1                    7
  38               Riegel 2006                                                                                               
  39        GESICA Investigators 2005         1                   0                     0                     1                    2
  40              Dunagan 2005                2                   0                     0                     1                    3
  41              Cleland 2005                1                   1                     2                     1                    5
  42             Capomolla 2004               1                   0                     0                     1                    2
  43             Galbreath 2004               1                   0                     0                     1                    2
  44               DeBusk 2004                2                   1                     1                     1                    5
  45              Goldberg 2003               1                   0                     0                     1                    2
  46              Laramee 2003                2                   1                     2                     1                    6
  47              McDonald 2002               1                   1                     2                     1                    5
  48               Riegel 2002                1                   2                     2                     1                    6
  49               Kasper 2002                1                   0                     1                     1                    3
  50              Krumholz 2002               1                   0                     0                     1                    2
  51               Jerant 2001                2                   2                     0                     1                    5
  52                Blue 2001                 1                   1                     1                     1                    4

###### Quality ratings for included randomized controlled trials using the Jadad quality assessment scale for hemodynamic monitoring.

  Number       Study       Randomization   Allocation concealment   Double blinding   Withdrawals and dropouts   Total score
  -------- -------------- --------------- ------------------------ ----------------- -------------------------- -------------
  1         Adamson 2016         1                   1                     1                     1                    4
  2         Adamson 2014         1                   1                     1                     1                    4
  3         Adamson 2011         1                   1                     1                     1                    4
  4         Bourge 2008          1                   1                     2                     1                    5

![Sensitivity analysis for hazard ratio on hospitalizations using telemonitoring.](jgc-15-04-298-s001){#s01}

![Funnel plot of standard error against the logarithm of hazard ratio for hospitalizations using telemonitoring.](jgc-15-04-298-s002){#s02}

![Funnel plot of precision against the logarithm of hazard ratio for hospitalizations using telemonitoring.](jgc-15-04-298-s003){#s03}
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![Sensitivity analysis for hazard ratio on hospitalizations using heomdynamic monitoring.](jgc-15-04-298-s006){#s06}

![Funnel plot of standard error against the logarithm of hazard ratio for hospitalizations using heomdynamic monitoring.](jgc-15-04-298-s007){#s07}
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![Subgroup analysis for hazard ratio on short-term hospitalizations using heomdynamic monitoring.](jgc-15-04-298-s009){#s09}

![Subgroup analysis for hazard ratio on long-term hospitalizations using heomdynamic monitoring.](jgc-15-04-298-s010){#s10}

![Subgroup analysis for hazard ratio on long-term hospitalizations using pulmonary pressure monitoring.](jgc-15-04-298-s011){#s11}

![Subgroup analysis for hazard ratio on long-term hospitalizations using right ventricular pressure monitoring.](jgc-15-04-298-s012){#s12}

4. Discussion {#s4}
=============

This is a systematic review and meta-analysis of randomized controlled trials and real-world studies on the effects of remote patient monitoring on hospitalization rates in heart failure, complementing previous meta-analyses.[@b11]--[@b13] The main findings are the following: (1) hospitalization rates can be reduced by remote patient monitoring using either telemonitoring or hemodynamic monitoring by 26% (95% CI: 17%--35%) and 40% (95% CI: 31%--47%), respectively; (2) telemonitoring reduced hospitalization rates by 24% in the short-term (≤ 6 months) and 27% in the long-term (≥ 12 months); and (3) hemodynamic monitoring reduced hospitalization rates by 45% in the short-term and 37% in the long-term.

Telemonitoring is a broad term referring to the making telephone contact with patients to enquire about symptoms, adherence to pharmacotherapy, and obtain information on clinically important parameters such as heart rate, blood pressure, body weight and urine output. This in turn enables appropriate advice to be offered to patients.[@b17] The benefits of home monitoring systems on hospitalization are possibly due to its good potential for detecting early signs of decompensation and reinforcement of patient\'s self-care education, and are especially useful for those who needs extra support, such as older and more frail patients.[@b87],[@b88] Telemonitoring appears to have limited potential in early detection of worsening heart failure, but most effective when patient education toward medical adherence and patient self-care efficacy are reinforced. These different effects of telemonitoring could be attributable to the wide distribution or the disparate outcome of the effects on hospitalization, and to the heterogeneity observed. There are different vital signs that could be used to provide a warning for heart failure decompensation. These are heart rate, heart rate variability,[@b89] blood pressure, body weight and urine output.[@b6],[@b89]--[@b91] For example, increases in body weight can predict acute decompensation requiring hospitalization.[@b91] However, a study found that diastolic blood pressure, systolic blood pressure x heart rate and diastolic blood pressure x heart rate, but not heart rate or systolic blood pressure by itself, predicted 3-month major adverse cardiac events.[@b90]

Hemodynamic monitoring refers to the continuous measurement of cardiac chamber or vascular pressures. Three devices are available: CardioMEMS (pulmonary arterial pressure),[@b92] Chronicle (right ventricular pressure)[@b93] and HeartPOD (left atrial pressure).[@b94] The rationale behind hemodynamic monitoring is that increases in intracardiac and pulmonary arterial pressures were detectable several weeks prior to worsening of clinical symptoms and signs.[@b4],[@b9] Subgroup analyses were performed for the different hemodynamic parameter measured. The evidence for pulmonary artery pressure monitoring is the strongest, with a 42% reduction in hospitalization rates. Right ventricular pressure monitoring tended to reduce hospitalization rates by around 31% but this was not statistically significant. It was not possible to perform a meta-analysis for left atrial monitoring, as only one study has been published to date. Nevertheless The LAPTOP-HF trial is currently ongoing and when completed will provide important data for determining whether left atrial monitoring will similarly reduce hospitalization rates in heart failure.[@b95]

Theoretically, hemodynamic monitoring should reduce hospitalization rates to greater extents than usual care or telemonitoring if patients were offered appropriate advice to mitigate abnormal cardiac physiology, such as fluid overload or bradycardia, by altering medication regimens at home so that hospitalization would not be necessary. Our meta-analysis found that the risk reduction for hospitalization using hemodynamic monitoring was slightly higher at 40% compared to 27% using telemonitoring, but this was not significantly different. This meta-analysis provides data that less-invasive remote monitoring by telemedicine is equally effective as more invasive forms of hemodynamic monitoring. The former approach may be more cost-effective and yet able to prevent hospitalizations. Therefore, healthcare resources can be focused on the patients who do require hospital admission, who can be offered additional investigations such as quantification of blood biomarkers and echocardiography for guiding their management.[@b96],[@b97]

4.1. Limitations {#s4a}
----------------

There are some limitations of this study that must be recognized. Firstly, we had observed a substantial heterogeneity for the HRs for the effects of telemonitoring on hospitalization rates. In our study, hazard ratios of randomized controlled trials and cohort studies, which are different study designs, were initially pooled together. A recent Cochrane review showed that there were no significant difference in the effective estimates between observational studies and randomized controlled trials, suggesting that factors other than study design are responsible for differences in outcomes.[@b98] However, in our subgroup analysis, we found that the pooled HR was significantly lower for cohort studies when compared to the HR for RCT. Therefore, meta-analysis should combine the effect estimates separately based on trial design. Moreover, this subgroup analysis resulted in a reduction of *I*^2^ to 72% for RCTs, suggesting that this contributed to the heterogeneity observed. Other sources, as assessed by our subgroup analyses, were the duration over which mortality was assessed (short-term versus long-term mortality) and whether the HRs were univariate or multivariate HRs. Secondly, we detected significant bias using both Begg and Mazumdar rank correlation test and Egger\'s test, in that the reported HRs skewed towards reduced hospitalization by telemonitoring. In other words, fewer HRs were from the studies reporting a lack of effect on hospitalization. Therefore, this may represent publication bias in which only positive findings were published by the journals, with negative results possibly not published. Thirdly, there were only four cohort studies that assessed hemodynamic monitoring. As only three RCTs with a limited number of subjects were conducted, future RCTs are needed for different types of hemodynamic monitoring systems, especially left atrial pressure monitoring, for which the HR was only available in one study and it was therefore not possible to conduct a subgroup analysis for this system. Finally, there is a lack of studies that directly compare hemodynamic monitoring to telemonitoring, which needs to be investigated in the future, especially given the invasive nature of hemodynamic monitoring systems.

4.2. Conclusions {#s4b}
----------------

This meta-analysis demonstrates that both telemonitoring and hemodynamic monitoring are equally effective approaches to reduce hospitalization rates in heart failure. Telemonitoring should be used more widely, since it is less invasive than hemodynamic monitoring and may be more cost-effective. However, direct comparisons between these modes of monitoring are needed in the future.

There are no conflicts of interests to be declared.
